Actively Recruiting
Molecular Diagnosis of Systemic Autoinflammatory Diseases
Led by Institut National de la Santé Et de la Recherche Médicale, France · Updated on 2026-03-05
300
Participants Needed
1
Research Sites
48 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Systemic autoinflammatory diseases (SAIDs) are rare and diverse conditions marked by periods of little or no symptoms interrupted by fever and inflammation affecting membranes and tissues. This research aims to discover new genes and specific biological patterns related to SAIDs, especially in patients whose disease causes are not yet known. The goal is to better understand SAIDs, speed up diagnosis, and support personalized treatment approaches. The study observes patients with clinical signs of aseptic inflammatory syndrome, such as fever that resolves on its own, abdominal pain or diarrhea, joint or muscle pain, chest pain or pericarditis, skin changes, sensory issues like uveitis or deafness, and kidney problems like amyloidosis. No investigational drugs or treatments are being given; instead, the project focuses on collecting data and samples to identify disease-causing gene mutations and cellular pathways over a 10-year period. Participants will be evaluated through clinical and biological assessments to identify mutations and biological signatures linked to SAIDs. Researchers will monitor disease pathways and explore options for personalized therapies based on findings. The study includes long-term observation up to 10 years, with no active treatment, allowing participants to continue their usual care during this time.
CONDITIONS
Brief Title
Molecular Diagnosis of Systemic Autoinflammatory Diseases
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients presenting with clinical and biological aseptic inflammatory syndrome including one or more of the following: spontaneously resolving fever, abdominal pain or diarrhea, joint or muscle pain, chest pain or pericarditis, skin involvement, sensory issues such as uveitis or deafness, or kidney involvement like amyloidosis.
You will not qualify if you...
- Adult subjects under legal protection measures such as guardianship, curatorship, or safeguard of justice.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 10 years
Participants undergo evaluation to identify disease-causing mutations and explore biological signatures related to systemic autoinflammatory diseases.
Visits as needed over the study period
Duration - Up to 10 years
Participants are monitored long-term to assess disease pathways and support personalized treatment development.
Visits as needed over the study period
Trial Site Locations
Total: 1 location
1
Trousseau Hospital
Paris, France, 75012
Actively Recruiting
Research Team
I
Irina GIURGEA
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here